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AbstrACt
Introduction Infertility is a worldwide problem and about 
10%–15% of all couples will be affected by the inability to 
have children. In approximately 50% of infertile couples, a 
male factor is involved. Most of the male infertile cases are 
characterised as ‘idiopathic’, except for a small percentage 
of cases which are causative by a genetic aetiology. In the 
past decade, the role of oxidative stress related to sperm 
quality has been researched thoroughly and estimated to be 
the problem in 25%–87% of male infertility cases. Impryl is a 
nutritional supplement which works on the metabolic system 
and the regulation of oxidative stress by activating the 
1- carbon cycle and therefore recycling of homocysteine. We 
hypothesise that the nutritional supplement Impryl in men of 
infertile couples might improve the ongoing pregnancy rate.
Methods and analysis We designed a multicentre, 
randomised, double- blind, placebo- controlled clinical trial. 
We aimed to include 1200 male adults aged 18–50 years, 
part of a couple that is diagnosed with infertility. The couple 
will either start or has already been started with fertility 
treatment, that is, expectative management (duration of 6 
months), intrauterine insemination (IUI) with or without mild 
ovarian stimulation or ovulation induction, either in vitro 
fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) 
treatment. Male participants will be randomised in either 
the Impryl or the placebo group, with identical appearance 
of the tablets to be distributed (doses: one tablet each day), 
for a total duration of maximal 6 months. Patients can start 
directly with fertility treatment and/or natural conception. 
The primary outcome is the number of ongoing pregnancies 
confirmed by ultrasound at ≥10 to 12 weeks, and conceived 
in the time window between randomisation up to and 
including month 6 of intervention use. Secondary outcomes 
are change in semen parameters between baseline and 
after 3 months of intervention in the IUI/IVF/ICSI group, 
based on (prewash) total motile sperm count. Furthermore 
the number of pregnancies conceived in the optimal 
intervention time window (after full spermatogenesis of 72 
days), overall number of pregnancies, time to pregnancy, 
embryo fertilisation rate in IVF/ICSI, embryo- utilisation 
rate in IVF/ICSI, number of miscarriages, live birth rate and 
adverse events are documented within the study period of 
15 months.
Ethics and dissemination The protocol is approved 
by the local medical ethical review committee at the 
Radboud University Medical Centre and by the national 
Central Committee on Research Involving Human Subjects. 
Findings will be shared with the academic and medical 
community, funding and patient organisations in order to 
contribute to optimisation of medical care and quality of 
life for patients with infertility.
trial registration numbers NCT03337360 and NTR6551.
IntroduCtIon
Infertility is a worldwide problem and about 
10%–15% of all couples will be affected by the 
inability to have children.1 In approximately 
strengths and limitations of this study
 ► This multicentre randomised double- blind, placebo- 
controlled trial will provide important information to 
patients with diagnosis of male infertility and to cli-
nicians about the efficacy of nutritional supplement 
Impryl with combined antioxidants.
 ► With a sample size of 1200 patients, this is up to 
date the largest randomised study with the use of 
nutritional supplements in fertility patients.
 ► Permuted block randomisation ensures treatment 
group numbers are evenly balanced, with stratifica-
tion for centre and type of infertility treatment.
 ► The optimal effect of Impryl is expected after full 
spermatogenesis of 72 days.
 ► The use of diagnostic tests to screen for oxida-
tive stress in semen samples (like sperm DNA- 
fragmentation tests or 8‐OH‐dG levels) could be of 
use in predicting the effect of Impryl on different 
patient groups. However, these tests are not used in 
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50% of infertile couples, a male factor is involved.1 2 In 
the past decade, the role of oxidative stress on sperm has 
been researched thoroughly and found to be the problem 
in 25%–87% of male infertility cases.3–9
All cells in the human body use oxygen to survive. In this 
process, toxic radicals with high reactive activity, so called 
reactive oxygen species (ROS), are produced as a conse-
quence.10 To scavenge these toxins, the body has devel-
oped a defence mechanism in which antioxidants play 
an important role. The production of ROS in sperm is a 
normal physiological process mostly regulated by cellular en 
extracellular antioxidative factors. However, when the ROS 
production overwhelms the natural antioxidant defence, 
increase of apoptosis is observed. Increased oxidative stress 
can occur due to environmental and lifestyle factors, such 
as smoking, stress, obesity and nutrition.10 In the reproduc-
tive tract, semen leucocytes and immature spermatozoa are 
major sources of ROS production.11 However, a low produc-
tion of ROS is also physiological and needed for adequate 
sperm functioning by supporting capacitation, maturation 
and hyperactivation.12 Spermatozoa are more vulnerable 
and prone to oxidative stress compared with other body 
cells because of the lack of cytoplasm.13 Cytoplasmic anti-
oxidant enzymes are important for directly scavenging 
and repairing the damage of ROS. However, in the sper-
matozoa, the cytoplasm is removed during the final stages 
of spermatogenesis, leaving them without these important 
enzymes to protect them from ROS altering the sperm 
DNA. Furthermore, the membrane of spermatozoa is rich 
in fatty acids, making them vulnerable for lipid peroxida-
tion by ROS, resulting in decreased flexibility of the sperm 
membrane and reduction of tail motion.13 For these reasons, 
spermatozoa are dependent on seminal plasma, which 
is rich in antioxidants. Examples of antioxidants already 
present within seminal plasma are ascorbic acid (vitamin 
C), α-tocopherol (vitamin E), glutathione (GSH), amino 
acids (taurine and hypotaurine), albumin, carnitine and 
carotenoids.14 Despite the common association between 
male infertility and oxidative damage, there is no WHO 
recommendation about which test to use for detecting 
sperm DNA damage and there are no standardised proto-
cols which could help global interpretation of the results. 
Men with sperm subject to increased oxidative stress may 
have normal seminal parameters but with DNA damage and 
therefore a lower chance of natural conception.15 16 Sperm 
DNA fragmentation (SDF) tests are available; however, 
most of them are expensive (roughly US$200–300 per test), 
complex and lack standardisation and validation.17 Further-
more, a recent meta- analysis showed that an association 
does not imply an actual predictive value.17 Examples of 
SDF test are deoxynucleotidyl transferase- mediated dUTP 
nick- end labelling (TUNEL), the comet assay (single- cell 
gel electrophoresis) or sperm chromatin structure assay, 
and another option is measuring the by- product of DNA 
oxidation called 8- hydroxydeoxyguanosine.
A recent Cochrane review suggested that antioxidant 
supplementation in male infertility might improve the 
outcomes in assisted reproductive technologies.18 However, 
the evidence was rated as low, and clinical studies showed 
contradictory results with sometimes even a negative effect 
of high doses of antioxidants due to reductive stress as a 
rebound effect.19 Alternatives were therefore explored, to 
support the natural antioxidant defences that are predicted 
to act within the modulation of the natural cellular homeo-
stasis without generating rebound effects. For example, 
the use of nutritional supplements supporting DNA meth-
ylation and the homocysteine pathway. Homocysteine 
is the end product of the 1- carbon cycle, feeding DNA 
methylation,and the starting substrate for the thiol GSH 
(l-γ-glutamyl- l- cysteinyl- glycine) de novo biosynthesis. GSH 
is the most important endogenous antioxidant, involved in 
maintaining the antioxidant balance in human tissues and 
directly involved in the elimination of ROS.20 Homocysteine 
is an inhibitor of the methylation process and a powerful 
pro- oxidant. It has a negative effect on spermatogenesis, 
and its concentration in the ejaculate is inversely correlated 
with fertility outcome.21 22 Dattilo et al stated that the ideal 
supplement should work by favouring homocysteine recy-
cling by restoring the efficiency of the 1- carbon cycle, there-
fore ensuring the availability of activated methyl groups for 
DNA methylation and feeding the intracellular antioxidant 
system by supporting GSH synthesis.23 In non- randomised 
pilot studies with such a 1- carbon cycle supporting nutri-
tional supplement Condensyl, the precursor of Impryl, 
there was a significant decline of DNA fragmentation index 
leading to an improvement of the clinical pregnancy rate. 
However, the quality of these studies for the impact on preg-
nancy rate is rather low due to the non- randomised nature 
and having no control group.21 24 25 Furthermore, the ideal 
parameters to measure DNA damage might not be DNA 
fragmentation but sperm- oxidation level which indirectly 
affects DNA damages.26 27
Impryl is a nutritional supplement mainly consisting of 
vitamin B, which works on the metabolic system by acti-
vating the 1- carbon cycle and recycling of homocysteine 
without the use of any direct strong antioxidant. Therefore, 
it could be more effective than other nutritional supple-
ments. The cost of Impryl is €30 for each 30 days of use.
It is well known that assisted reproduction technologies 
are expensive, with the cost per in vitro fertilisation (IVF) 
treatment in the Netherlands estimated to be between 
€2885 and €5259 and the cost of an intrauterine insemi-
nation (IUI) cycle between €497 and €1123, depending 
on the use and doses of medication during ovarian stimula-
tion.28–30 Therefore, substantial cost savings could be made 
if the use of relatively inexpensive nutritional supplements 
would lead to a shorter time to pregnancy with less treat-
ment cycles necessary or even better, when the use of more 
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blinding of participants and investigators. We conduct 
this study in 15 academic and non- academic hospitals in 
The Netherlands, at the department of gynaecology and/
or reproductive medicine.
The study protocol was designed using the recommen-
dations of the Standard Protocol Items: Recommenda-
tions for Interventional Trials guidelines.31
The study is currently ongoing; the first participant 
was included on 30 May 2018. We expect to include the 
last participant in June 2022 and study completion by 
December 2023.
Participants
In order to be eligible to participate in this study, a subject 
must meet all of the following criteria.
Inclusion criteria
 ► Couples with failure to conceive for at least 12 months 
and starting with expectative management (EM) or 
couples starting with first/ second/third cycle of IUI 
(with or without mild ovarian stimulation) or first/ 
second/third cycle of IVF or intracytoplasmic sperm 
injection (ICSI).
 ► Male aged 18–50 years.
 ► Female partner aged 18–43 years.
 ► Both male and female are willing and able to give 
informed consent.
Exclusion criteria
 ► Planned or performed testicular sperm extraction or 
percutaneous epididymal sperm aspiration.
 ► Use of donor semen, cryopreserved semen or electro-
ejaculated semen or donor oocytes.
 ► Ovulation induction (OI) without IUI.
 ► IVF for an absolute tubal factor.
 ► Embryo transfer after preimplantation genetic 
diagnosis.
 ► Known endocrine abnormalities related to male infer-
tility, or use of fertility enhancing drugs such as clomi-
phene citrate or follicle- stimulating hormone.
 ► Known genetic abnormalities related to male 
infertility.
 ► Known urological abnormality, such as a varicocele or 
bilateral cryptorchidism.
 ► Use of other vitamins or nutritional supplements with 
antioxidant effect.
Withdrawn or unblinded participants will not be 
replaced. They will not be reincluded in the study once 
they dropped out, and their identification number and 
treatment will not be reused.
sample size calculation
We aimed to recruit 1200 male participants as a part of an 
infertile couple, based on the following data and power 
calculation.
Overall, the number of ongoing pregnancies in IVF and 
ICSI in the Netherlands was 19.8% and 21.5%, respec-
tively, per started fresh cycle in 2015.32 The number of 
ongoing pregnancies in IUI is estimated to be around 
5% to 13% per cycle, around 18% after three cycles and 
20%to 30% after six cycles.33–35 Based on Radboudumc 
data, the ongoing pregnancy rate in EM is estimated 
around 20% after 6 months.
A Cochrane review estimated the increase in clinical 
pregnancy rates after use of antioxidants with an OR of 
3.43 (95% CI 1.92 to 6.11) based on seven RCTs with a 
total of 522 men.36 However, this concerns low- quality 
evidence, and the included population in this Cochrane 
review was couples with male factor subfertility, whereas 
in our study, we also include couples with unexplained 
infertility. Therefore, we assumed a more conservative 
OR of 1.5. Assuming a 20% ongoing pregnancy rate in 
the placebo group, this reflects in an expected pregnancy 
rate of 27.3% in the Impryl group.
The study is designed as a superiority trial. Based on 
the above mentioned data, we expect a 7.3% increase in 
ongoing pregnancy number when men are treated with 
Impryl compared with placebo. However, after randomi-
sation, patients can directly start with both intervention 
and achieving a pregnancy, either spontaneously or with 
fertility treatment. In these first months, the effect of 
the intervention is expected to be suboptimal due to the 
duration of the spermatogenesis (72 days before whole 
renewal). Therefore, we adjusted the expected increase 
of 7.3% to a more realistic effect of 6.5%. We assume an 
equal increase in all fertility groups (meaning EM, IUI 
and IVF/ICSI) from 20% to 26.5%.
To test the effect of Impryl on the probability of ongoing 
pregnancy, a sample size of 600 men per treatment group 
(1200 in total) is needed, assuming differences in ongoing 
pregnancy rates of 6.5% and an expected ongoing preg-
nancy rate of 20% in the placebo group, a two- sided 
alpha of 5% and a beta of 24% (ie, 76% power). As we 
expect the number of participants lost to follow- up to be 
minimal, we will allocate 600 patients to both the inter-
vention and the placebo arm. Figure 1 shows the distribu-
tion of the number of participants for the three different 
types of fertility treatment (EM, IVF/ICSI and IUI).
Investigational product/intervention
Impryl tablets will be produced by Labomar SRL 
(compliant with European Good Manufacturing Practice 
(GMP)), which will also produce an identical- looking 
placebo tablet. Impryl is a food supplement and is there-
fore not considered an investigational medicinal product. 
To assess product quality, we have quality assessment 
documents of both the food supplement and placebo: 
Summary of Product Characteristics (SPC; see online 
supplementary file 1), Certificates of Analysis, certificate 
of GMP and ISO 9001 form. Intervention will start directly 
after randomisation.
All couples will receive our standard care for infertility 
according to the guidelines of the Dutch Society of Obstet-
rics and Gynaecology. After diagnostic workup, couples 
will either start with EM (6 months), IUI, IVF or ICSI. 
Participants will take study supplement for a maximum of 
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Figure 1 Flowchart study design. ICSI, intracytoplasmic sperm injection; IUI, intrauterine insemination; IVF, in vitro fertilisation.
6 months, even if the fertility intervention (6× IUI of 1× 
IVF/ICSI cycles) is not completed.
Cotreatment with other vitamins or supplements is 
prohibited. If vitamins or supplements are already used 
by men, a washout period of 3 months is recommended. 
Patients using other supplements will be excluded or 
reported as protocol violation If after randomisation 
it appears that a patient still uses other supplements 
(reported in the online questionnaire), they will be tele-
phonically contacted and asked to stop the use of other 
supplements. After this stop, there is a washout period of 
72 days (duration of spermatogenesis). If no pregnancy 
occurs within this washout period, the patient and data 
can still be included.
randomisation and treatment allocation
All couples visiting a fertility specialist for the first time or 
for evaluation of fertility treatment will be informed on 
this study. Prior to or at their actual appointment, they will 
receive the patient information (PIF) from the fertility 
specialist (specialised nurse or doctor). Randomisation 
will be performed after signed informed consent has 
been obtained, using a web- based application (Castor). 
We will use permuted block design, stratified for fertility 
treatment (first) and recruiting centre (second). Block 
sizes are flexible. Participants will be randomised in a 1:1 
ratio to study medication (Impryl) or placebo. Assign-
ment to medication, using the randomisation list, will be 
performed either at the local centre or at Radboudumc 
by an independent person. This person is neither partic-
ipating in clinical treatment nor processing the study 
data. Randomisation outcome is either A (Impryl) or B 
(placebo).
Coding starts immediately after informed consent 
has been obtained. In Castor, each patient will receive 
a combination of one letter and three numbers. The 
code will not provide any information about the received 
intervention (Impryl or placebo). The list of codes corre-
sponding with PIF and received medication will be saved 
in an separate file, locked (either digital with password 
or a locked cabinet), only accessible for the independent 
person who did the randomisation.
The study is double blinded. All personnel, the 
researchers and patients will remain blinded to the inter-
vention being received, except the personnel performing 
randomisation and distributing the study medication. 
The indications for breaking the randomisation code 
are serious adverse event (SAE), serious adverse reaction 
(SAR) and suspected unexpected serious adverse reac-
tions (SUSAR), as instructed by the local medical ethical 
review committee (METC), or in a dire emergency, as 
directed by the principal investigators or trial manager. 
Every site has access to a deblinding form in which 
patients details, reason for deblinding, statement of prin-
cipal site investigator, date and time of intervention stop 
and randomisation allocation will be reported. The prin-
cipal site investigator will inform the coordinating investi-
gator about the deblinding.
At all study sites, the person distributing the study medi-
cation is an unblinded employee of the department of 
reproductive medicine or gynaecology who is not involved 
in the treatment of the patient nor involved in the data 
collecting of the research. Drug accountability will be 
performed in line with good clinical practice (GCP) 
requirements. The investigator is responsible for drug 
accountability, and these tasks will be delegated to the 
primary investigators at the sites. We will log all dispensing 
of the investigational product on a drug accountability log. 
On every distributing study site, there will be a batch of 
study medication stored at room temperature, no special 
precautions. An unblinded authorised employee of the 
department of reproductive medicine (or gynaecology) 
will distribute the study medication after randomisation 
has been performed by Castor. The flag label (identifica-
tion A=Impryl or B=placebo) will be removed from the 
box and the randomisation number noted (handwritten) 
on the medication box. Thereafter, the box will be 
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Figure 2 Timeline study (T in months). EM, expectative management; ICSI, intracytoplasmic sperm injection; IUI, intrauterine 
insemination; IVF, in vitro fertilisation.
handed over to the patient. On the patient identification 
and drug accountability log (either digital or on paper), 
the following details will be reported: date of issue, study 
(randomisation) number, batch number, expiration date, 
amount dispensed, current storage amount, randomiser/
distributor initials, hospital number, patient name and 
initials, date of birth and monitoring check.
All unblinded personnel performing randomisation 
will be trained by a site initiation to perform randomisa-
tion in Castor EDC and distribution of medication. A log 
list of all personnel involved in the study, with blinding 
status, responsibilities and signature, will be saved.
Unblinding will be performed when the study has 
ended, database is locked and protocol violators have 
been defined.
Patients are not asked to return study medication 
because this would mean an extra burden for the patients: 
an extra visit for all EM patients and some IUI/IVF/ICSI 
patients. Furthermore, patients could also forget a strip at 
home that they did not collect or put in the box. Since it 
is a supplement and not medication, there are no specials 
precautions for destruction or disposal.
Participant timeline and intervention
All couples will receive standard care for infertility 
according to the guidelines of the Dutch Society of Obstet-
rics and Gynaecology (NVOG). Initially, from the active 
start of the study and first inclusion in June 2018, couples 
in the EM or IUI group could start directly with both the 
intervention (study medication) and starting to conceive. 
However, in the IVF or ICSI treatment group participants 
had to use study medication at least three consecutive 
months before using semen for the actual IVF or ICSI to 
be sure of an optimal treatment effect of the interven-
tion. However, in April 2020, there was a protocol change, 
which allowed all participants from each treatment cate-
gory (EM, IUI and IVF or ICSI) to start directly with both 
the intervention (study medication) and fertility treat-
ment and/or natural conception at the same time. This 
amendment was made to make the situation more real-
istic and more in line with daily practice, with taking into 
account the gradual process of spermatogenesis rather 
than only an effect after 72 days, and was approved by the 
local ethics committee. After diagnostic workup, couples 
will either start with EM (6 months), IUI, IVF or ICSI, 
according to the NVOG guidelines. Participants will take 
study medication (Impryl or placebo) for a maximum of 
6 months, even if the fertility intervention (6× IUI or 1× 
IVF/ICSI cycle) is not completed. Use of the food supple-
ment or placebo will be stopped earlier when a pregnancy 
is achieved. Participants will be followed for 15 months 
after randomisation for detecting live births. Figure 2 
shows the participant timeline.
During the study, participants are asked to report on 
baseline characteristics, lifestyle changes and pregnancy 
outcomes by short online questionnaires (see online 
supplementary file 2).
 ► Baseline: directly after randomisation, patients will 
receive an automatic email invitation to provide 
baseline information online in the Castor database 
system.
 ► Monthly: during use of study medication (6 months), 
participants will be asked to report on occurrence 
of pregnancy (with date of positive test), changes in 
lifestyle, consumed total amount of study medication 
(used boxes and tablets) and occurrence of adverse 
events (AEs). They will receive an automatic email 
invitation.
 ► Follow- up: 15 months after randomisation, partici-
pants will receive an automatic email with invitation 
for the last short questionnaire. They will receive 
questions about fertility treatment and pregnancy 
outcome (ability to achieve a pregnancy, occurrence 
of miscarriage or childbirth, date of delivery, gesta-
tional age, mode of delivery, complications of delivery 
and birth weight, sex, congenital abnormalities and 
health of the neonate).
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At least two semen analyses will be performed at two 
time points in this study: the first semen analysis will be 
performed during diagnostic workup (standard care and 
analysis according to WHO criteria37) and the second one 
after approximately 3 months of using study medication 
for participants having the IUI or IVF/ICSI treatment. 
We decided not to perform a second semen analysis 
in the EM group due to the fact that they present with 
normal semen parameters at intake, and we want to avoid 
the burden of an extra visit.
If a clinical pregnancy is achieved, a routine ultrasound 
will be performed in the first trimester between 5 and 
9 weeks to determine the vitality of the fetus. A second 
routine ultrasound will be performed around 10–12 
weeks to estimate the due date. To minimalise the amount 
of extra site visits, we decided that this standard ‘due date’ 
ultrasound at 10–12 weeks of pregnancy is enough for 
determining the primary outcome (ongoing pregnancy). 
The ultrasound can be performed in the midwife prac-
tice. Information about the outcome of this ultrasound is 
reported in the 15 months questionnaire.
outcome measures
This study investigates the effect of food supplement 
Impryl on ongoing pregnancy rate when used by the male 
of an infertile couple.
Primary endpoint
The number of ongoing pregnancies, conceived in the 
time window between randomisation up to and including 
month 6 of intervention use.
Secondary endpoints
 ► Number of pregnancies conceived in the optimal 
intervention time window, that is, between start of 
month 4 until the end of month 6.
 ► Overall number of pregnancies, meaning the cumula-
tive pregnancy number up to 9 months after start of 
intervention.
 ► Time to pregnancy defined as (1) the time between 
randomisation and reaching ongoing pregnancy 
(confirmed by ultrasound) and (2) the time between 
start of fertility treatment during the study (EM, IUI 
and IVF/ICSI) and reaching ongoing pregnancy.
 ► Change in semen parameters in the IUI/IVF/ICSI 
group based on prewash total motile sperm count, 
allocated to change in treatment category (EM, IUI, 
IVF, ICSI).
 ► Improvement between Impryl and control group in 
fertilisation rate and embryo utilisation rate (EUR) 
in the IVF/ICSI group. Fertilisation rate is defined as 
the percentage of oocytes with 0 pronucleus (PN) or 
≥2 PN after insemination (IVF) or injection (ICSI). 
Abnormal fertilisation such as 3 PN will be recorded, 
in case this percentage differs or increases in the 
study group. The EUR is defined as the number of 
high quality embryos obtained, embryo’s used at 
transfer plus the number of embryos frozen, divided 
by the number of zygotes obtained in a cycle. Due 
to the differences in embryo evaluation and embryo 
selection criteria for cryopreservation, we decided to 
measure the relative increase in fertilisation and use 
rate observed for each clinic.
 ► Number of miscarriages, defined as non- vital intrau-
terine pregnancy before 16 weeks of gestation.
 ► Live birth rate (beyond 24 weeks, defined as the birth 
of a living child) within study period of 15 months.
 ► Adverse effects.
Male baseline parameters that are collected by online 
questionnaires are age, length, weight, ethnicity, alcohol/
drugs/nicotine use, use of vitamins/steroids or other 
supplements, diet specifics (options: normal, vege-
tarian, vegan, gluten- free, diary free, others), medication 
use, activities that cause increased scrotal temperature 
such as often visiting a sauna, taking a hot bath or race 
cycling, general health, operations or trauma in genital 
area, exposure to toxins in the environment, conception 
of previous children, duration of infertility and type of 
diagnosis of infertility. Furthermore, the age and parity 
of the female partner has to be documented, as well as 
the occurrence of endometriosis or an anovulatory cycle.
handling and storage of data and documents
Data will be collected in an online registration system 
(Castor) by the coordinating investigator or research 
nurses. Data handling will be done anonymously, with 
the patient code only available to the local investigator 
and the research nurse working in the local centre. 
The results will be extracted from Castor. If there are 
missing data, this will be mentioned along with the 
reason. The data will be preserved for the duration of 15 
years. The handling of personal data complies with the 
Dutch Personal Data Protection Act (in Dutch: De Wet 
Bescherming Persoonsgegevens).
Monitoring and quality assurance
Monitoring will be performed in compliance with GCP 
and other rules and regulations in order to achieve high- 
quality research and secure patient safety. Monitoring 
will be done by an independent party of the Radboud 
University Medical Centre. The monitor is certified and 
has been approved by the local METC.
statistical analysis
We will analyse all data on an intention- to- treat basis. Data 
of patients who are lost to follow- up will be included in 
their randomised group:
 ► Patients who are lost to follow- up during the treat-
ment period are considered not to have achieved a 
pregnancy.
 ► Patients who are lost to follow- up right after achieving a 
pregnancy of less than 8 weeks of gestation are consid-
ered not to have achieved an ongoing pregnancy.
 ► Patients who are lost to follow- up right after achieving 
a pregnancy of 8 or more weeks of gestation are 
considered to have achieved an ongoing pregnancy.
copyright.
 on O













pen: first published as 10.1136/bm




7Smits R, et al. BMJ Open 2020;10:e035069. doi:10.1136/bmjopen-2019-035069
Open access
In addition, a per- protocol analysis will be performed 
for the primary outcome and the secondary outcomes 
overall pregnancy number, time to pregnancy, number of 
miscarriages and live birth rate.
Descriptive statistics will be calculated to check for 
major dissimilarities between study groups with respect 
to baseline information. Baseline data will be described 
quantitatively. For continuous variables, we will examine 
the distribution of the observations, and if normally 
distributed, we will summarise them as means with SDs. If 
they are not normally distributed, then medians and IQRs 
will be reported. For dichotomous data, we will provide 
counts and proportions.
The primary outcome variable ‘ongoing pregnancy’ will 
be assessed as follows. The ongoing pregnancy percent-
ages as observed in the trial will be presented for both 
treatment arms, overall and separately for the three strata 
(ie, EM, IUI and IVF/ICSI). In order to adjust for possible 
imbalances between the treatment groups, the pregnancy 
percentages and differences in pregnancy percentages 
between the experimental and control group, and the 
corresponding 95% CIs will be estimated using a fixed 
effects binomial model with an identity link, including 
intervention, fertility treatment, centre and female age 
(centred). If this model does not converge, a logit link 
will be used.
Time to ongoing pregnancy will be evaluated by the 
Kaplan- Meier approach; differences between the two 
arms will be tested with the log- rank test. Similar anal-
yses will be conducted per stratum (EM, IUI or IVF/
ICSI). The other secondary outcomes (overall pregnancy 
number, number of miscarriages, live birth rate, fertili-
sation rate and EUR) will be evaluated similarly to the 
primary outcome. Changes in semen analysis, leading to 
different fertility treatment categorisations, will be calcu-
lated with descriptive statistics. Furthermore, AEs will be 
summarised. Sensitivity analyses will be performed to 
evaluate possible effects in case of protocol amendments.
The per- protocol population will consist of all 
randomised patients without any major deviation from 
the protocol. A major protocol deviation is defined as
 ► Use of other nutritional supplements.
 ► Intake of study medication of less than 75% of the 
prescribed amount.
AEs, sAEs and susArs
AEs are defined as any undesirable experience occurring 
to a subject during the study, whether or not considered 
related to Impryl. All AEs reported by the subject or 
observed by the investigator or his staff will be recorded.
A SAE is any untoward medical occurrence or effect 
that
 ► Results in death.
 ► Is life threatening (at the time of the event).
 ► Requires hospitalisation or prolongation of existing 
inpatients’ hospitalisation.
 ► Results in persistent or significant disability or 
incapacity.
 ► Is a congenital anomaly or birth defect.
 ► Any other important medical event that did not 
result in any of the outcomes listed previously 
due to medical or surgical intervention but could 
have been based on appropriate judgement by the 
investigator.
An elective hospital admission will not be considered as 
a SAE. The investigator will report all SAEs to the sponsor 
and METC without undue delay after obtaining knowl-
edge of the events.
SUSARs are all untoward and unintended responses 
to the food supplement or placebo related to any dose 
administered.
Unexpected adverse reactions are SUSARs if the 
following three conditions are met:
1. The event must be serious.
2. There must be a certain degree of probability that the 
event is a harmful and an undesirable reaction to the 
medicinal product under investigation, regardless of 
the administered dose.
3. The adverse reaction must be unexpected, that is to 
say, the nature and severity of the adverse reaction are 
not in agreement with the product information as re-
corded in
 – SPC for an authorised medicinal product.
 – Investigator’s Brochure for an unauthorised medic-
inal product.
The sponsor will report expedited the following SUSARs 
through the web portal ToetsingOnline to the METC:
 ► SUSARs that have arisen in the clinical trial that was 
assessed by the METC.
 ► SUSARs that have arisen in other clinical trials of the 
same sponsor and with the same medicinal product, 
and that could have consequences for the safety of the 
subjects involved in the clinical trial that was assessed 
by the METC.
The remaining SUSARs are recorded in an overview 
list (line listing) that will be submitted once every half 
year to the METC. This line listing provides an overview 
of all SUSARs from the study medicine, accompanied by a 
brief report highlighting the main points of concern. The 
expedited reporting of SUSARs through the web portal 
Eudravigilance or ToetsingOnline is sufficient as notifica-
tion to the competent authority.
The expedited reporting will occur not later than 15 
days after the sponsor has first knowledge of the adverse 
reactions. For fatal or life- threatening cases, the term will 
be maximal 7 days for a preliminary report with another 
8 days for completion of the report.
Annual safety report
In addition to the expedited reporting of SUSARs, the 
sponsor will submit, once a year throughout the clinical 
trial, a safety report to the accredited METC, competent 
authority and competent authorities of the concerned 
member states.
This safety report consists of
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 ► A list of all suspected (unexpected or expected) 
SARs, along with an aggregated summary table of all 
reported SARs, ordered by organ system, per study.
 ► A report concerning the safety of the subjects, 
consisting of a complete safety analysis and an evalua-
tion of the balance between the efficacy and the harm-
fulness of the medicine under investigation.
Patient and public involvement
Patients were not involved in the development of this 
research. However, the overall results of the study will be 
communicated to the study participants by sending the 
end product (article) to the provided email address.
EthICs, dIssEMInAtIon And sAfEty MonItorIng
The protocol and all protocol modifications are approved 
by the local METC at the Radboud University Medical 
Centre and by the national Central Committee on 
Research Involving Human Subjects with protocol ID 
NL61414.091.17.
This study is registered in the American registry for 
clinical studies and trials (https:// clinicaltrials. gov) and 
the Dutch Trial registry ( www. trialregister. nl). The inves-
tigator obtains written informed consent before study 
participation from all participants.
Due to the known safety of Impryl, the study team and 
ethics committee decided the establishment of a data 
safety monitoring board is not necessary. However, the 
trial is monitored by an independent party according to 
the monitor plan. After the first three inclusions, every 
centre is visited by the monitor, followed by a yearly 
visit. Given the low risk on AEs of a nutritional supple-
ment, an interim analysis or safety surveillance by a data 
safety monitoring board is not indicated. All participants 
are insured by the sponsor in case of harm due to trial 
participation.
The study is conducted according to the principles of 
the Declaration of Helsinki (latest version WMA General 
Assembly 2008, Seoul) and in accordance with the 
Medical Research Involving Human Subjects Act. Directly 
after study inclusion, we assigned a random ID code to 
the participant, which will be used on all documents to 
ensure confidentiality.
A manuscript with the results of the primary study will 
be published in a peer- reviewed journal. The results of 
this study will be shared with the academic and medical 
community, funding and patient organisations in order to 
contribute to optimisation of care for infertility patients.
On completion of the trial, and after publication of the 
primary manuscript, data requests can be submitted to 
the researchers
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